Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.61 |
| ▸ | CCNC | P24863 | 6/20 | 0.54 |
| ▸ | CDK8 | P49336 | 6/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19663215 | 0.86 | MKNK1 (0.61) | CHEK1MAP4K4MKNK1MKNK2CCNC | |
| SCHEMBL19662826 | 0.86 | MKNK1 (0.61) | CHEK1MAP4K4MKNK1MKNK2CCNC | |
| SCHEMBL21400335 | 0.84 | MKNK1 (0.60) | CHEK1MAP4K4MKNK1MKNK2CCNC | |
| SCHEMBL3716144 | 0.83 | MKNK1 (0.56) | CHEK1MAP4K4MKNK1MKNK2CCNC | |
| SCHEMBL13984679 | 0.81 | MKNK1 (0.57) | CHEK1MAP4K4MKNK1MKNK2CCNC | |
| SCHEMBL21237215 | 0.81 | MKNK1 (0.61) | CHEK1MAP4K4MKNK1MKNK2CCNC | |
| SCHEMBL3758736 | 0.81 | MAP4K4 (0.57) | CHEK1MAP4K4PIM1MET | |
| SCHEMBL248730 | 0.81 | — | — | |
| SCHEMBL6625312 | 0.80 | CHEK1 (0.63) | CHEK1MAP4K4MKNK1MKNK2MET | |
| SCHEMBL21816369 | 0.80 | KMO (0.54) | CHEK1MAP4K4MKNK1MKNK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1391476-A | Vasopressin agonist formulation and process | AMERICAN CYANAMID CO (US) | 2003-01-15 | — | — | CN | claimed |
| EP-1216045-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | American Cynamid Company (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001022969-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | AMERICAN CYNAMID COMPANY (US) | 2001-04-05 | — | — | WO | claimed |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| CN-115427035-B | ENL/AF9 YEATS inhibitors | 洛克菲勒大学 | 2025-04-22 | — | — | CN | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| CN-115427035-A | ENL/AF9YEATS inhibitors | 洛克菲勒大学 | 2022-12-02 | — | — | CN | disclosed |
| EP-4076440-A1 | INHIBITORS OF ENL/AF9 YEATS | The Rockefeller University (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-1216045-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | American Cynamid Company (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002010146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001022969-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | AMERICAN CYNAMID COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |
| CN-1260781-A | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | SMITHKLINE BEECHAM PLC (GB) | 2000-07-19 | — | — | CN | disclosed |
| EP-1000062-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0975593-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| CN-1224418-A | Tetrahydroisoquinoline derivs. as modulators of dopamine D3 receptors | SMITHKLINE BEECHAM PLC (GB) | 1999-07-28 | — | — | CN | disclosed |
| WO-1999006409-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1998050358-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | CHEK1 1454/4885MAP4K4 260/4885MKNK1 831/4885 |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | MLLT3, YEATS2, MLLT1 | CHEK1 3731/4885MAP4K4 1754/4885MKNK1 1451/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | CHEK1 415/4885MAP4K4 3626/4885MKNK1 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.